Surrogate Endpoints in Medicine

نویسندگان

  • Sudhir Srivastava
  • John A. Wagner
چکیده

A surrogate endpoint is defined as a biomarker intended to substitute for a clinical endpoint, such as an incidence, or mortality. The evidence supporting the linkage of a biomarker to accurately substitute for a clinical endpoint may be derived from epidemiologic studies, clinical trials, in vitro analysis, animal models, and simulated biologic systems. Analytical epidemiological studies of the relationship between putative intermediate endpoints and disease help postulate the nature of the interrelationship among epidemiological risk factors, intermediate endpoints, and disease. This presents problems in a system where more than one causal path exists. Adjustment for the presence of standard epidemiological factors may have different interpretations. Specifically, the disappearance of an association between a putative intermediate endpoint and disease after adjustment for the presence of some epidemiological risk factors may have opposing interpretations: either the intermediate endpoint is causal, related to disease and mediates the effects defined by the epidemiologic risk factor or it has nothing to do with disease in a causal sense. Several contributors throughout this issue have described and used a variety of biomarkers in treatment trials. Selected biomarkers may be proposed as potential surrogate endpoints, however, relatively few are likely to achieve this status because of the complexity of disease mechanisms and the limited capability of a single biomarker to reflect the collective impact of multiple chemopreventive and therapeutic effects on outcome. It is likely that the future studies would employ a panel of biomarkers as a surrogate endpoint, which would require additional biologic studies and insights. A biomarker does not have to be causally related to a disease to play a valuable role in early detection and intervention of that disease. However, causally related biomarkers, i.e., surrogate endpoints, if measured with precision, are likely to have the strongest association with disease.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma

With the recent progress in imaging technologies for assessment of structural damage in glaucoma, a debate has emerged on whether these measurements can be used as valid surrogate endpoints in clinical trials evaluating new therapies for the disease. A discussion of surrogates should be grounded on knowledge acquired from their use in other areas of medicine as well as regulatory requirements. ...

متن کامل

Links between analysis of surrogate endpoints and endogeneity.

There has been substantive interest in the assessment of surrogate endpoints in medical research. These are measures that could potentially replace 'true' endpoints in clinical trials and lead to studies that require less follow-up. Recent research in the area has focused on assessments using causal inference frameworks. Beginning with a simple model for associating the surrogate and true endpo...

متن کامل

Bayesian meta‐analytical methods to incorporate multiple surrogate endpoints in drug development process

A number of meta-analytical methods have been proposed that aim to evaluate surrogate endpoints. Bivariate meta-analytical methods can be used to predict the treatment effect for the final outcome from the treatment effect estimate measured on the surrogate endpoint while taking into account the uncertainty around the effect estimate for the surrogate endpoint. In this paper, extensions to mult...

متن کامل

Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors

BACKGROUND: Surrogate measures for cardiovascular disease events have the potential to increase greatly the efficiency of clinical trials. A leading candidate for such a surrogate is the progression of intima-media thickness (IMT) of the carotid artery; much experience has been gained with this endpoint in trials of HMG-CoA reductase inhibitors (statins). METHODS AND RESULTS: We examine two sep...

متن کامل

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011

BACKGROUND Surrogate endpoint trials test strategies more efficiently but are accompanied by uncertainty about the relationship between changes in surrogate markers and clinical outcomes. METHODS AND RESULTS We identified cardiovascular trials with primary surrogate endpoints published in the New England Journal of Medicine, Lancet, and JAMA: Journal of the American Medical Association from 1...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 18  شماره 

صفحات  -

تاریخ انتشار 2002